BIONTECH SE SPON. ADRS 1
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.
Read
Commented by Juliane Zielonka on March 3rd, 2022 | 13:12 CET
Cardiol, BioNTech, Novartis - Inventory at three high-flyers
Good news, this time from Cardiol Therapeutics. Both the US FDA and regulatory authorities in Brazil and Mexico have given the green light for the inclusion of patients already vaccinated against COVID-19 in the LANCER trial. The opening with respect to this patient group increases the likelihood of a speedy trial completion. The pandemic cannot be over until global efforts are made to fight the virus together. So BioNTech will build a plant in Rwanda. And Novartis, as an experienced Big Pharma giant, illustrates through its quarterly figures how valuable the pharmaceutical industry as a whole can be as an investment.
Read
Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET
BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?
Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?
Read
Commented by Stefan Feulner on February 24th, 2022 | 10:23 CET
Lufthansa, mm2 Asia, BioNTech - Clear the way for the rebound
After the strong increase by the Omicron variant, the infection numbers are decreasing, and the world is breathing a sigh of relief. Due to the high vaccination rates, politicians are loosening existing restrictions. It is hard to believe, going to cinemas, restaurants and even discos is allowed again. Bookings for the travel season are increasing daily, and flying, provided you don't want to go to Kiev or Odesa at the moment, is possible at any time. Due to the almost two-year standstill, there are interesting opportunities to participate in the revived business, especially in the entertainment industry.
Read
Commented by André Will-Laudien on February 22nd, 2022 | 13:05 CET
BioNTech, Moderna, Valneva, Cardiol Therapeutics: The gold rush is over!
The mild progression of the Omicron variant and the associated massive relaxations of the Corona measures in many countries weighs heavily on the prospects of the vaccine manufacturers. That is because the winter is drawing to a close, clinical shortages are not occurring, and vaccination rates do not want to increase despite massive public campaigns. Meanwhile, even those in power realize that enforcing a general vaccination requirement could become a hot legal ride under the current circumstances. For the biotech sector and vaccine producers, in particular, this is a reason for profit-taking for the time being. Here are a few further ideas.
Read
Commented by Stefan Feulner on February 14th, 2022 | 12:17 CET
BioNTech, XPhyto, Steinhoff - Explosives for the stock markets
The situation on the stock markets remains tense. Due to the persistently high inflation figures, voices are becoming increasingly louder, calling for far more than the originally planned 3 interest rate hikes by the FED for this year. The ECB should also not be long in finally abandoning its ultra-loose monetary policy. And to make matters worse, the situation in Ukraine is threatening to escalate. The US already reacted to the tense situation and withdrew embassy staff from the Ukrainian capital Kiev.
Read
Commented by Nico Popp on February 10th, 2022 | 11:14 CET
BioNTech, Cardiol Therapeutics, Peloton: Future check on pandemic stocks
There are pandemic stocks that are already out today. But there are also pandemic stocks that are only now taking off operationally. We take a look at three stocks and do a future check: Where has the pandemic only provided the initial spark, and where is the hype irretrievably over?
Read
Commented by Stefan Feulner on February 9th, 2022 | 12:20 CET
BioNTech, Barsele Minerals, Pfizer - Markets facing a turnaround
The vaccination pace in Germany continues to decline. According to experts, the Omicron variant could be the end of the pandemic and the change to an endemic. Is this why we have already seen the highs in vaccine manufacturers? With the FED's plan to raise interest rates in several steps, technology stocks corrected sharply, while new life was breathed into shares from the financial services sector. Companies in the gold sector should also be in strong demand over the long term because one thing is certain, even if the pandemic goes away, government debt will remain.
Read
Commented by André Will-Laudien on February 3rd, 2022 | 13:55 CET
Novavax, XPhyto Therapeutics, BioNTech, Valneva - The vaccine blockbusters are on the move again!
It is on again with the vaccine producers. Experts consider the pandemic to be over by the summer of 2022, but vaccination rates are still low, and infection figures are rushing from record to record. Meanwhile, mandatory vaccination by law is also a daily topic of discussion, dividing society into at least two camps. According to the thinking of those currently taking action, the right to freedom of bodily integrity probably ceases when third parties could suffer a disadvantage as a result of one's own decision. It's so easy to knit laws under the postulate of "protection & general welfare," and the individual right to liberty under the Basic Law is thus unceremoniously nullified. After all, members of parliament are supposed to be able to vote without factional coercion. We evaluate the chances of the well-known biotech protagonists!
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read